CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

itacitinib

Small moleculeexperimental

Clinical trial activity

55 trials · 25 clinical orgs · 0 marketing orgs

Phase 1
25
Phase 2
38
Phase 3
2
Phase 4
0

Earliest trial started Mar 1, 2012 (NCT01626573)

Timeline

2010s

  1. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1
Mol. weight
553.52 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • incb039110
  • incb039110
  • incb039110
  • incb-039110
  • incb-039110
  • incb-39110
  • incb-39110
  • itacitinib
  • itacitinib
  • itacitinib
  • itacitinib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05823571Phase 1Jul 6, 2023Incyte, Johns Hopkins University
NCT05757219Phase 2May 19, 2023Incyte, University of South Florida
NCT05660421Phase 2Jan 31, 2023Incyte, Vanderbilt University
NCT05364762Phase 2Nov 23, 2022City of Hope National Medical Center, National Cancer Institute (NCI)
NCT04789850Phase 2Jan 31, 2022Assistance Publique - Hôpitaux de Paris
NCT05063110Phase 2Oct 1, 2021Assistance Publique - Hôpitaux de Paris, Incyte
NCT04859946Phase 1Sep 1, 2021Incyte, University of Texas at Houston
NCT04629508Phase 2Jan 9, 2021Incyte
NCT04446182Phase 2Dec 31, 2020Incyte, University of Utah
NCT04640025Phase 2Dec 21, 2020Incyte
NCT04591431Phase 2Oct 7, 2020University of Roma La Sapienza
NCT04509700Phase 2Aug 3, 2020Incyte
NCT04339101Phase 2Jun 1, 2020City of Hope National Medical Center, National Cancer Institute (NCI)
NCT04239989Phase 1May 31, 2020University of Texas at Houston
NCT04071366Phase 2Jan 31, 2020Incyte
NCT04220632Phase 1/Phase 2 (Phase 2)Jan 31, 2020Innovent Biologics (Suzhou) Co. Ltd.
NCT04127721Phase 2Jan 30, 2020National Cancer Institute (NCI), University of Texas at Houston
NCT04200365Phase 2Dec 31, 2019Incyte, SCRI Development Innovations
NCT04129931Phase 2Nov 30, 2019National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill
NCT04061421Phase 1/Phase 2 (Phase 2)Oct 31, 2019Astex Pharmaceuticals, Inc., Incyte, Theradex, Vanderbilt University
Showing 20 of 55 trials
Page 1 / 3

Organizations

Research & Development (25)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
IncyteFor profit422942012
University of Texas at HoustonAcademic/Hospital4422019
National Cancer Institute (NCI)Government3012020
Assistance Publique - Hôpitaux de ParisAcademic/Hospital2212021
Baylor UniversityAcademic/Hospital201—
City of Hope National Medical CenterAcademic/Hospital2212020
University of PennsylvaniaAcademic/Hospital2212018
Vanderbilt UniversityAcademic/Hospital2212019
Washington University in St. LouisAcademic/Hospital2222016
Astex Pharmaceuticals, Inc.For profit1012019
AstraZenecaFor profit1012016
Columbia UniversityAcademic/Hospital1112019
Harvard UniversityAcademic/Hospital1112018
Icahn School of Medicine at Mount SinaiAcademic/Hospital1112019
Imperial College LondonAcademic/Hospital1112018
Innovent Biologics (Suzhou) Co. Ltd.For profit1112020
Johns Hopkins UniversityAcademic/Hospital1112023
National Heart, Lung, and Blood Institute (NHLBI)Government1012019
SCRI Development InnovationsFor profit1112019
TheradexFor profit1012019
25 organizations
Page 1 / 2